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OBJECTIVES: To better inform decision-makers on how practice may deviate from 
scientiﬁ c evidence, and for which factors further research is particularly worthwhile, 
through parameterizing factors that may impact the generalizability of economic 
evaluations. METHODS: We modeled the long-term cost-effectiveness of trastuzumab 
in early breast cancer. Based on a review, ﬁ ve real-world factors that could inﬂ uence 
the cost-effectiveness of trastuzumab in daily practice were identiﬁ ed: comparators, 
patient consequences, clinical practice, patient mix, and professional use. To explore 
the impact of these factors on (cost-)effectiveness, parameters were added to the model. 
Parameter values, ranges, and distributions were based on literature and expert 
opinion. Analyses were performed without (trial scope) and with real-world factors 
included (decision scope). Cost-effectiveness acceptability curves were drawn and 
value of information was analyzed. RESULTS: In the trial-scope analysis, the FinHer 
regimen dominated the other two trastuzumab regimens, and was cost-effective com-
pared to usual care (c1.845/QALY). In the decision-scope analysis, the HERA regimen 
was most effective, amounting to c50.746/QALY gained compared to FinHer. At a 
ceiling ratio of c30.000, the FinHer regimen was most likely to be cost-effective in 
both analyses. However, this probability was higher in the trial-scope analysis (98%) 
than in the decision-scope analysis (54%). Hence, the probability that in the real world 
a wrong decision is made is considerably higher than suggested in the trial-scope 
analysis. The parameter for which in the real world further research was most valuable 
was the credibility of the FinHer regimen. CONCLUSIONS: Incorporating parameters 
that improve generalizability is feasible, even in absence of evidence. Parameterizing 
the uncertainty of these parameters provides an estimation of how likely it is for each 
comparator to be cost-effective in the real world. Also, it informs decision-makers and 
researchers for which parameters further research is most valuable, for instance, in 
patient access schemes. 
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OBJECTIVES: Diabetes is a chronic and progressive disease that for many patients 
requires initiation and intensiﬁ cation of insulin in order to sustain glycemic control 
and thereby lower risk of long-term complications. Insulin intensiﬁ cation, however, 
can have some negative consequences for patients in the form of increased risk of 
hypoglycemic events. This analysis asks the question to what extent the administration 
vehicle, preﬁ lled pen versus vial and syringe, has an impact on the risk of hypoglycemic 
events. METHODS: This is a retrospective database analysis comparing the incidence 
of hypoglycemia-related health-care utilization between patients that were previously 
naïve to short-acting insulin initiating the short-acting insulin analogue, insulin aspart 
(IAsp), in either a vial or in a preﬁ lled disposable pen (FlexPen®). Data were derived 
from health-care claims for individuals with employer-sponsored primary or Medicare 
supplemental insurance between 2004 and 2007. The analysis was conducted using 
logistic regression technique controlling for age, gender, diabetes type, pre-index 
hypoglycemic incidence, pre-index diabetes treatments, and daily consumption of 
IAsp. Evaluation period was 12 months. RESULTS: The cohorts consisted of 5523 
vial patients and 6065 FlexPen® patients. Mean age of the two cohorts were 53.6 
and 56.2 years (P < 0.0001) in vial and FlexPen® groups, respectively. Fifty-one 
percent and 54% (P = 0.05) of the populations were males. Generally, a larger propor-
tion the FlexPen® versus the vial cohort were already on an insulin regimen (basal or 
premix). Mean number of annual hypoglycemia-related health-care utilization inci-
dence in the period following initiation of IAsp were 1.27 and 0.87 (P < 0.0001) for 
vials and FlexPen®, respectively. After multivariate adjustment, the odds ratio of 
hypoglycemic incidence with vials versus FlexPen® was 1.36 (CI: 1.20–1.54). CON-
CLUSIONS: After controlling for potential confounders, the incidence of hypoglyce-
mia-related health-care utilization were 36% higher when initiating IAsp in a vial 
compared to initiation with FlexPen®.
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OBJECTIVES: To estimate the number of hospitalizations for severe hypoglycemia 
(SH) in patients with diabetes mellitus in Spain and assess the differences amongst 
regions. METHODS: A retrospective study was conducted using the hospital 
Minimum Basic Data Set (CMBD) which collects up to 73% of all hospitalizations in 
Spain. All hospitalization episodes of diabetic patients in which SH was the principal 
or secondary diagnosis for hospitalization during 2007 were accounted for. a SH was 
deﬁ ned as a hypoglycemic episode which requires hospitalization. RESULTS: The 
number of SH episodes as primary diagnosis was estimated at 8242 in relation to total 
discharged patients with a diagnosis of DM2 (primary and secondary) at 496,660 
patients (1.66% of total). When the number of SH as primary diagnosis is related to 
the total number of discharged patients with a diagnosis of DM2 as the primary 
diagnosis (23,343 patients), the percentage of episodes become 35.31%. The number 
of SH as a secondary diagnosis for hospitalization was estimated at 17,302 episodes: 
16,649 in patients with DM2 (96.2%) and 653 in patients with DM1 (3.8%). For 
DM2 when SH as secondary diagnosis are added to primary diagnosis, the number 
of episodes is 24,891, which means that hypoglycemia diagnosis accounts for 5.01% 
of hospitalizations for DM2 patients (496,660 patients). Catalonia shows the highest 
number of SH, with 1477 episodes as a primary diagnosis in DM2 patients (17.9% 
of total) and 3836 episodes of SH as a secondary diagnosis in DM2 patients (23.0% 
of total). CONCLUSIONS: Severe hypoglycemia represents a signiﬁ cant cause for 
hospitalization for DM2 patients in Spain: incidence of 1.66% estimated in the overall 
DM2 patients increases to 35.3% in the subpopulation of patients discharged for DM2 
as primary diagnosis. There is a great variation in the incidence of severe hypoglycemia 
between regions.
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OBJECTIVES: To assess the efﬁ cacy and safety of dipeptidyl peptidase-4 (DPP-4) 
inhibitors, including saxagliptin, sitagliptin, and vildagliptin, in type 2 diabetic 
patients. METHODS: Meta-analysis was conducted for efﬁ cacy (Hemoglobin A1c and 
weight) and safety outcomes (hypoglycemia and other adverse events). Both published 
and unpublished randomized controlled trials (RCTs) for type 2 diabetic patients using 
DPP-4 inhibitors were included. RCTs were selected if criteria included a duration of 
at least 12 weeks and they compared DPP-4 inhibitors with placebo or other hypo-
glycemic medications. Two reviewers independently assessed trials for inclusion and 
extracted data. Differences were resolved by consensus. RESULTS: Of 579 potentially 
relevant articles identiﬁ ed, 118 were retrieved for detailed evaluation, and 52 met 
inclusion criteria. DPP-4 inhibitors signiﬁ cantly reduced hemoglobin A1c compared 
with placebo (weighted mean difference, −0.851% [95% conﬁ dence interval {CI}, 
−1.057% to −0.645%]) and were noninferior to other hypoglycemic agents (0.117% 
[95% CI, −0.042% to 0.276%]). DPP-4 inhibitor increased weight compared with 
placebo (0.186 kg [95% CI, 0.128 kg to 0.244 kg]), but the increase was not signiﬁ -
cantly different from other hypoglycemic agents. Also compared with placebo, DPP-4 
inhibitors had an increased risk of hypoglycemia (odd ratio [OR], 1.430 [95% CI, 
1.198–1.708]) and any adverse event (OR, 1.072 [95% CI, 1.003–1.145]). However, 
the risk of experiencing hypoglycemia or any adverse event was signiﬁ cantly lower in 
patients using DPP-4 inhibitors compared to other hypoglycemic agents (OR, 0.307 
[95% CI, 0.247–0.381]; OR, 0.828 [95% CI, 0.765–0.896], respectively). a similar 
result was also seen with serious adverse events (OR, 0.834 [95% CI, 0.699–0.996]) 
and GI adverse events (OR, 0.810 [95% CI, 0.715–0.917]) for DPP-4 inhibitors versus 
other oral antidiabetic medications. CONCLUSIONS: DPP-4 inhibitors had similar 
efﬁ cacy for hemoglobin A1c reduction and weight loss, and had a decreased risk of 
hypoglycemia and other adverse events compared with other hypoglycemic agents.
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OBJECTIVES: The study reported the utilization of oral antidiabetic drugs (OADs), 
glycemic control, hypoglycemia, and adverse events of type 2 diabetes mellitus 
(T2DM) patients with OADs therapy during their clinical visits in urban hospitals in 
China. METHODS: The study was a cross-sectional survey conducted at 75 hospitals 
in nine cities in China. There were 9577 T2DM patients with OADs therapy com-
pleted the questionnaires. The survey period was from December 3, 2008 to July 31, 
2009. Patients’ self-report on their diabetes condition and the latest health examina-
tion was used to evaluate the diabetes management situation. Descriptive statistics 
method was used for the analyses. RESULTS: A total of 51.1% of the patients were 
male, the mean age (±SD) was 59.5 ± 12.7 years, and the mean duration of disease 
(±SD) was 7.9 ± 6.3 years. The percentage of patients treated with biguanides, sulfo-
nylurea, meglitinides, glitazones, α-glucosidase inhibitors, and others (including tra-
ditional Chinese medicine) were 78.4%, 65.1%, 14.0%, 12.6%, 31.1%, and 18.1% 
respectively. Blood glucose control was inadequate, the mean HbA1c and fasting blood 
glucose were 9.1 ± 2.4% and 9.4 ± 3.4 mmol/L, respectively. Only 7.9% of the 
patients achieved the treatment target (HbA1c < 6.5%). There were 15.3% patients 
who experienced hypoglycemia episodes in the last 4 weeks, the mean hypoglycemia 
rates were 26.0/patient/year, of which major hypoglycemia rates were 7.8/patient/year, 
and nocturnal hypoglycemia rates were 6.5/patient/year. There were 60.3% OADs 
